We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Hepatitis C Drug Battle: What’s Going On?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Hepatitis C Drug Battle: What’s Going On?
BusinessFinancePublic Health

Hepatitis C Drug Battle: What’s Going On?

DavidEWilliams
DavidEWilliams
Share
4 Min Read
SHARE
Just give me the cheapest one

Just give me the cheapest one

Makers and buyers of new Hepatitis C drugs have been slugging it out in public lately. What’s going on and what are the broader implications?

Just give me the cheapest one

Just give me the cheapest one

Makers and buyers of new Hepatitis C drugs have been slugging it out in public lately. What’s going on and what are the broader implications?

Pharmacy benefit managers, health plans and drug makers have been gearing up for this fight for a while. Many baby boomers contracted Hepatitis C from IV drug use and other excesses back when they were flower children. But available treatments have been difficult to tolerate and not always that successful, so as a result there is a huge pent up demand for an easy-to-tolerate, curtive treatment. Enter Gilead with its Sovaldi (sofosbuvir).

The roughly $85,000 price tag for a course of treatment is pretty high, but Sovaldi is not nearly as expensive as some other specialty products that no one makes a big stink about. The real issue here is the large number of potential patients and the overall near term financial impact of Sovaldi on those who are paying the bills. Sovaldi has a decent value proposition, too: save money and improve quality of life by avoiding liver transplants.

More Read

Medical Educators Need to Take Charge and Help Deflate Medical Bills
Should Your Medical Practice Have a Twitter Account?
Why Health Care Costs Are So High. Docs Don’t Know What Things Cost
Entrepreneurs Must Integrate Mission-Driven Strategic Investors
Health Care Buzz Today

Meanwhile, payers led by Express Scripts, a large pharmacy benefit manager, have been beating the drum against the high price of Sovaldi. They have been talking out of both sides of their mouth: they don’t want price controls (after all, that would put them out of business), but they do want lower prices that they consider to be fair.

Express Scripts has been licking its wounds for some time, writing big checks to Sovaldi’s maker Gilead. But now there is a competing drug on the market from AbbVie, called Viekera Pak (a stupid name in case you want my opinion). Express Scripts made a bold move by striking an exclusive deal with AbbVie in an effort to lock Gilead out. Things looked a little tough for Gilead at first, but now the pendulum is swinging in the other direction. First, Express Scripts competitor CVS made an exclusive deal with Gilead. That wasn’t a huge surprise. But then, Express Scripts’ biggest customer, Anthem also made an exclusive deal with Gilead. The Anthem deal undercut the value of Express Scripts’ arrangement with AbbVie and undermined Express Scripts’ credibility.

My guess is that none of the payers extracted a massive discount from the companies. I also think doctors will retain a reasonable degree of discretion in choosing which product to prescribe. None of the exclusive deals bar patients from getting the competitor’s drug; they just make it harder.

What’s striking about the Hepatitis C battle is that it’s clearly all about the money. None of the parties have really tried to claim that the deals are based on clinical considerations.

What we don’t know yet is what the battle over Hepatitis C drug pricing means for other high price specialty drugs. For example, will payers push back more aggressively on pricing or availability for cancer drugs? Will they try to pit manufacturers against one another? How steep will any discounts be? Will doctors and patients rebel? Will they enlist state legislatures and Congress? How about the courts?

Stay tuned as we find out.

photo: incurable_hippie / photopin cc

TAGGED:hepatitis Cpharmasovaldi
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Left to Our Own Devices

April 14, 2011
DTC Marketing, Medical Device Marketing, Medical Technology Marketing
BusinessFinance

Medical Device DTC Marketing: Digital Co-Marketing and the Power of the Referral (Part 2 of 4)

July 21, 2014

Analysis of Spending in U.S., Canada on Health IT Vendors in 2014

September 2, 2013
free podcasts
Business

9 Best Practice Tips and Techniques for Superior Podcasts and Audio Content

December 2, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?